The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Beyond maximum grade: A novel method to assess toxicity over time in clinical trials of targeted therapy in lymphoma.
 
Gita Thanarajasingam
No Relationships to Disclose
 
Pamela J. Atherton
No Relationships to Disclose
 
Levi Pederson
No Relationships to Disclose
 
Paul J Novotny
No Relationships to Disclose
 
Thomas Matthew Habermann
No Relationships to Disclose
 
Jeff A. Sloan
No Relationships to Disclose
 
Axel Grothey
Consulting or Advisory Role - Amgen (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst); Sanofi (Inst)
Research Funding - Bayer (Inst); Boston Biomedical (Inst); Eisai (Inst); Genentech/Roche (Inst); Lilly (Inst); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Boston Biomedical; Bristol-Myers Squibb; Genentech/Roche
 
Shaji Kumar
No Relationships to Disclose
 
Thomas E. Witzig
Stock and Other Ownership Interests - Valeant Pharmaceuticals International
Consulting or Advisory Role - Amgen
Research Funding - Acerta Pharma (Inst); Celgene (Inst); Novartis (Inst); Spectrum Pharmaceuticals (Inst)